Enhanced Suppression Of HIV-1 by the Combination of Cytidine Dideoxynucleoside Analogues And CTP Synthase Inhibitors
Description of Invention:
The present invention provides for compositions and methods to increase the
activity of cytidine-based anti-HIV drugs and to overcome resistance of human
immunodeficiency virus (HIV) to cytidine-based anti-HIV drugs. More specifically, the invention provides for compositions, methods of preventing or inhibiting the spread of a virus, methods of treatment, and methods of improving the antiviral activity of a cytidine dideoxynucleoside analogue drug in patients with viral infection. Typical drugs suitable for potentiation by this method include ddC, 3TC, D4C (2',3'- dideoxycytidine-2',3'-ene), 5-fluoroddC, and 3'-alpha-fluoroddC. The virus may be HIV-2, HTLV-1, HTLV-2, SIV, HBV, but most preferably HIV-1.
Inventors:
W-Y Gao DG Johns H Mitsuya V Marquez (NCI)
Patent Status:
DHHS Reference No. E-073-1997/0 Licensing Status: This technology is no longer available for licensing.
For Additional Information Please Contact: Sally Hu PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5606
Email: hus@mail.nih.gov
Fax: (301) 402-0220
